GSK’s China sales may be down 30 pct on bribery scandal -analysts

LONDON, Sept 23 (Reuters) - GlaxoSmithKline's sales in China may have dropped 30 percent since authorities accused it of corruption, disrupting its ability to market medicines in the country, accordin…
Read the full story: Reuters: Healthcare